Valneva sells Priority Review Voucher from FDA for $103M

Valneva announced earlier today that it sold the Priority Review Voucher it received from the Food and Drug Administration for $103M. The company was awarded a tropical disease PRV in November 2023 following FDA approval of Ixchiq, its single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus. Valneva said will invest proceeds from the sale into its R&D projects, including the co-development of its Phase 3 vaccine candidate against Lyme disease, additional clinical trials for its chikungunya vaccine Ixchiq and the expansion of the company’s clinical pipeline. Thomas Lingelbach, Chief Executive Officer of Valneva, said, “This non-dilutive capital provides an important source of additional funding to advance the continued development of our clinical pipeline. As shown with the recent approval of our chikungunya vaccine, we remain committed to growing our portfolio of vaccines addressing unmet medical needs which have the potential to transform people’s lives.”